US Approves Shionogi's Oral COVID-19 Preventive Drug

GOOGL shares fell 4.1% in the last close, with the RSI approaching oversold territory at 32.6. The MACD line remains below the signal line and in negative territory, indicating short-term weakness. The stock is trading below its 20-day and 50-day moving averages, reflecting a bearish technical outlook. Although the news headline is not directly related to Google's operations, developments in the healthcare sector, such as drug approvals, may reduce interest in technology stocks. The likelihood of a continued downtrend in the short term is high.

The news indicates that a product potentially rivaling Pfizer's COVID-19 drug Paxlovid has received approval. Technical indicators are already weak: RSI at 38.6 is in the sell zone, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. A 1.95% decline in the last 24 hours suggests the market is pricing in the news negatively. Short-term pressure is expected to persist, but the pace of decline may be limited as the stock approaches oversold territory.

Johnson & Johnson (JNJ) shares have declined 3.5% over the past 24 hours, with the Relative Strength Index (RSI) approaching oversold territory at 34.3. However, the Moving Average Convergence Divergence (MACD) remains negative and below its signal line. News headlines indicate that a competitor's drug has received approval, which could create competitive pressure on JNJ's COVID-19 treatment and vaccine portfolio. In the short term, technical indicators are weak, and the news may be perceived negatively, suggesting the downtrend could continue. However, the low RSI level also implies some potential for a rebound, leading to a medium-high confidence level in this assessment.

GSK shares fell 4.66% in the last close, with the RSI dropping to 21, entering oversold territory. The MACD line remains below the signal line and in negative territory, confirming weak momentum. News that a competitor's COVID-19 prophylactic drug has been approved could negatively impact GSK's potential market share in this area. In the short term, the downtrend is expected to continue due to weak technical indicators and competitive pressure. Although the oversold region may signal a possible buying opportunity, upside movement may remain limited under current conditions.